Clinical trials: Diabetes Type II
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver…
- Conditions
- Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01975935
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan
Type 1 Diabetes Mellitus
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
This is a randomized placebo controlled study to test whether a single 14 course of treatment with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss of insulin secretory capacity in…
- Trial name
- NCT00378508
- Testing
- mAb hOKT3gamma1(Ala-Ala), Teplizumab
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
- Trial name
- NCT01422876
- Testing
- high dose FDC, BI 10773 high dose
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,405 people
- Sponsor
- Boehringer Ingelheim
Type-2 Diabetes Mellitus
Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider…
- Trial name
- NCT01766778
- Testing
- LAF237 (vildagliptin), Metformin
- Where
- 4 sites in Hong Kong
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Pilot Trial of the Nutrition-Supported Diabetes Education Program
This is a pragmatic, pilot randomized controlled trial (RCT) of the Nutrition-Supported Diabetes Education Program (NU-DSMP). This study will test the feasibility and preliminary impact of providing diabetes-tailored food support…
- Trial name
- NU-DSMP (NCT05067452)
- Testing
- Food support, Case-management
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Type 2
A Multi-center 12-week Study of HMS5552 in T2DM
This study evaluates the safety, tolerability, efficacy and population PK of HMS5552 in type 2 diabetic adult subjects,there will be 5 groups ,4 groups will receive HMS5552,while 1 will receive placebo.
- Trial name
- NCT02561338
- Testing
- HMS5552
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Hua Medicine Limited
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Patients
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in…
- Trial name
- NCT01298518
- Testing
- PF-04620110
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.
- Trial name
- NCT00824616
- Testing
- MK-0941, Insulin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
- Trial name
- NCT00286442
- Testing
- Alogliptin and metformin, Metformin
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 527 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 2 diabetes mellitus. The study will be conducted in participants with type 2 diabetes on insulin injection therapy to…
- Trial name
- NCT03305822
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
- Trial name
- T2DMCT (NCT01589445)
- Testing
- Pioglitazone hydrochloride, Metformin hydrochloride
- Where
- Bangladesh
- Volunteers
- 77 people
- Sponsor
- University of Dhaka
Type 2 Diabetes, Coronary Heart Disease
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to examine the existence of heart abnormalities in patients with diabetes and the effect of pioglitazone in correcting these abnormalities.
- Trial name
- NCT01588470
- Testing
- pioglitazone
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type2 Diabetes, Heart Failure
Effect of Ertugliflozin on Cardiac Function in Diabetes
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who…
- Trial name
- ERTU-GLS (NCT03717194)
- Testing
- Ertugliflozin
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Soo Lim
Cardiovascular Diseases, Atherosclerosis
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Type 2 Diabetes, Insulin Resistance
- Trial name
- NCT04167761
- Testing
- Ertugliflozin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Type II Diabetes, Primary Health Care
INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes
In 2016, the American Diabetes Association (ADA) published its first-ever recommendations for integrating medical and psychosocial care for patients with Type II Diabetes Mellitus (DMII) and common mental and behavioral health…
- Conditions
- Type II Diabetes, Primary Health Care, Behavioral Health
- Trial name
- NCT04461405
- Testing
- INTEGRATE-D
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Type 2 Diabetes, Cardiovascular Disease
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
- Trial name
- NCT01609582
- Testing
- TAK-875
- Where
- 584 sites in United States, Argentina and 30 more
- Volunteers
- 3,207 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2…
- Trial name
- LIRA-Ramadan™ (NCT01917656)
- Testing
- liraglutide, metformin, sulphonylurea
- Where
- 41 sites in Algeria, India and 5 more
- Volunteers
- 343 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
- Trial name
- NCT00778622
- Testing
- Metformin XR
- Where
- 14 sites in China
- Volunteers
- 371 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.